MDRNA, Inc. Acquires Patent Estate to Broaden Its RNAi Intellectual Property Portfolio

BOTHELL, WA--(Marketwire - October 22, 2008) - MDRNA, Inc. (NASDAQ: MRNA) announced today that it has acquired intellectual property related to non-nucleotide chemistry (Unlocked Nucleic Acid) technology from RiboTask ApS, a privately held Danish company specializing in the development and synthesis of novel RNA chemistries. The technology will permit MDRNA to stabilize and provide drug-like properties to RISC and Dicer length siRNAs in a novel and proprietary manner. Terms of the agreement were not disclosed.